Observational Study to Evaluate Neurodevelopmental Status in Pediatric Patients With Hunter Syndrome (MPS II)
- Conditions
- Mucopolysaccharidosis (MPS)Hunter Syndrome
- Registration Number
- NCT01822184
- Lead Sponsor
- Shire
- Brief Summary
Hunter syndrome (Mucopolysaccharidosis II, \[MPS II\]) is a rare, genetically linked lysosomal storage disease (LSD) caused by deficiency of the enzyme, iduronate-2-sulfatase (I2S). Most MPS II patients will present with some degree of neurodevelopmental involvement, ranging from severe cognitive impairment and behavioral problems to mildly impaired cognition. This is an observational study; no investigational treatment will be administered. The primary objective of this study is to evaluate the neurodevelopmental status of pediatric patients with MPS II over time and to gain information to guide future treatment studies in this patient population.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 100
Patients must meet all of the following criteria to be considered eligible for enrollment:
- a. The patient has a deficiency in iduronate-2-sulfatase enzyme activity AND b. The patient has a documented mutation in the iduronate-2-sulfatase gene. OR c. The patient has a normal enzyme activity level of one other sulfatase
- The patient is male, and is at least 2 years of age and less than 18 years of age at the time of informed consent.
- The patient must have sufficient auditory capacity at enrollment, with or without hearing aids, in the Investigator's judgment to complete the required protocol testing, and be compliant with wearing the aids on scheduled study visits.
- The patient, patient's parent(s), or legally authorized guardian(s) has voluntarily signed an Institutional Review Board / Independent Ethics Committee-approved informed consent and/or assent form(s), as applicable.
Patients who meet any of the following criteria will be excluded from the study.
- The patient has clinically significant non-Hunter syndrome-related CNS involvement or medical or psychiatric comorbidity(ies) which, in the investigator's judgment, may interfere with the accurate administration and interpretation of protocol assessments, affect study data, or confound the integrity of study results.
- The patient has a general conceptual ability score (GCA) or a developmental quotient on the cognitive scale below 55 at Screening.
- The patient is participating in an interventional clinical trial or has participated in an interventional clinical trial within 30 days prior to enrollment; participation in non interventional observational studies is permitted.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Neurodevelopmental parameters of cognitive function over time in pediatric patients with MPS II 24 months Neurodevelopmental parameters of adaptive function over time in pediatric patients with MPS II 24 months
- Secondary Outcome Measures
Name Time Method Reported adverse events 24 months Type and severity measurements
Medication usage 24 months Quality of life 24 months
Trial Locations
- Locations (7)
Ann & Robert H. Lurie Children's Hospital of Chicago
🇺🇸Chicago, Illinois, United States
Hospital Infantil Universitario
🇪🇸Madrid, Spain
Hospital Universitario Austral
🇦🇷Pilar, Buenos Aires, Argentina
Central Manchester University Hospitals NHS Foundation Trust Willink Biochemical Genetics Unit, St. Mary's Hospital
🇬🇧Manchester, M13 9wl, United Kingdom
Childrens Hospital & Research Center Oakland
🇺🇸Oakland, California, United States
University of North Carolina Division of Genetics and Metabolism
🇺🇸Chapel Hill, North Carolina, United States
Instituto Nacional De Pediatria
🇲🇽Mexico City, Mexico